CSTL (Castle Biosciences) Short-Term Debt: $1.7 Mil (As of Mar. 2026)


CSTL Castle Biosciences Inc CSTL
77 GF Score
Price $23.72
GF Value $29.20
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences Short-Term Debt?

Castle Biosciences CSTL -3.42% 77 Short-Term Debt is $1.7 Mil as of Mar. 2026. GuruFocus rates CSTL with a GF Score™ of 77/100 and a GF Value™ of $29.20 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Castle Biosciences's Short-Term Debt for the quarter that ended in Mar. 2026 was $1.7 Mil.

Castle Biosciences's quarterly Short-Term Debt increased from Sep. 2025 ($0.0 Mil) to Dec. 2025 ($0.4 Mil) and increased from Dec. 2025 ($0.4 Mil) to Mar. 2026 ($1.7 Mil).

Castle Biosciences's annual Short-Term Debt increased from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.3 Mil) and increased from Dec. 2024 ($0.3 Mil) to Dec. 2025 ($0.4 Mil).

Castle Biosciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Castle Biosciences Short-Term Debt Related Terms

Castle Biosciences Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences Short-Term Debt Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.28 0.42

Castle Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 1.94 0.00 0.42 1.67
CSTL
77GF Score
Castle Biosciences Inc CSTL
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $1.7 Mil mean?
Castle Biosciences (CSTL) has a Short-Term Debt of $1.7 Mil as of Mar. 2026.
Is Castle Biosciences' Short-Term Debt too high?
Castle Biosciences' current Short-Term Debt is $1.7 Mil. Overall, Castle Biosciences has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Short-Term Debt compare to FLGT and MYGN?
Castle Biosciences' Short-Term Debt of $1.7 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Diagnostics & Research company?
A good Short-Term Debt depends on the Medical Diagnostics & Research industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Castle Biosciences's current Short-Term Debt is $1.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.20, compared to a current price of $23.72 — trading 18.8% below its estimated fair value. The current Short-Term Debt is $1.7 Mil. Castle Biosciences' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Short-Term Debt is $1.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $23.72 is trading 18.8% below its estimated GF Value™ of $29.20. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

  • Short-Term Debt: $1.7 Mil
  • GF Value™: $29.20 vs. price of $23.72 (18.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
77GF Score

Get the complete analysis for CSTL

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.72
Price
$29.20
GF Value